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Short peptide motifs in unstructured regions of clathrin-adaptor proteins recruit clathrin to
membranes to facilitate post-Golgi membrane transport. Three consensus clathrin-binding pep-
tide sequences have been identiﬁed and structural studies show that each binds distinct sites
on the clathrin heavy chain N-terminal domain (NTD). A fourth binding site for adaptors on
NTD has been functionally identiﬁed but not structurally characterised. We have solved high
resolution structures of NTD bound to peptide motifs from the cellular clathrin adaptors β2
adaptin and amphiphysin plus a putative viral clathrin adaptor, hepatitis D virus large antigen
(HDAg-L). Surprisingly, with each peptide we observe simultaneous peptide binding at multiple
sites on NTD and viral peptides binding to the same sites as cellular peptides. Peptides contain-
ing clathrin-box motifs (CBMs) with the consensus sequence LΦxΦ[DE] bind at the ‘arrestin
box’ on NTD, between β-propeller blades 4 and 5, which had previously been thought to bind
a distinct consensus sequence. Further, we structurally deﬁne the fourth peptide binding site
on NTD, which we term the Royle box. In vitro binding assays show that clathrin is more read-
ily captured by cellular CBMs than by HDAg-L, and site-directed mutagenesis conﬁrms that
multiple binding sites on NTD contribute to efﬁcient capture by CBM peptides.
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1 | INTRODUCTION
Clathrin mediates vesicular transport between post-Golgi membranes
in eukaryotes and is targeted to speciﬁc membranes by interactions
with clathrin adaptor proteins.1–3 Individually these interactions are
weak,4 but because clathrin polymerization drives the growth of a
network of available binding sites, a wide range of adaptors and
accessory factors may be recruited and retained at sites of coated pit
formation.2,5–7
Clathrin:adaptor interactions are typically driven by linear peptide
motifs in the unstructured regions of clathrin adaptors that bind the
N-terminal β-propeller domain (NTD) of the clathrin heavy chain at
several distinct sites (reviewed in reference 8): the “clathrin-box motif”
(CBM), consensus sequence LΦxΦ[DE] (where x denotes any amino
acid, Φ denotes a bulky hydrophobic residue and [DE] is a glutamate
or aspartate), binds in a groove between blades 1 and 2 of the NTD
β-propeller3,9,10; and the “W box” consensus PWxxW, binds the cleft
near the centre of the NTD β-propeller.11,12 Thirdly, an extended sur-
face loop of the arrestin 2 long isoform (arrestin2L) has been shown to
occupy the “arrestin box”, a site lying between blades 4 and 5 of the
NTD that binds peptides with consensus [LI][LI]GxL.13 More recently,
a fourth adaptor binding site on the clathrin NTD, between blades
6 and 7, was deﬁned by Willox and Royle14 on the basis of functional
experiments in HeLa cells expressing clathrin heavy chain mutated in
the NTD. This last study found that even a single functional NTD site
was sufﬁcient to sustain transferrin uptake.
The observation that any individual binding site on NTD is sufﬁ-
cient to sustain clathrin-mediated endocytosis of the transferrin
receptor raises several questions. Does it reﬂect promiscuity in
the binding of clathrin-interaction motifs, such that an individual
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clathrin-binding motif can bind to different sites on NTD, or does it
instead suggest intrinsic redundancy in the recruitment of adaptors
such that endocytosis still proceeds even when an entire ‘class’ of
clathrin-binding motif is prevented from binding clathrin? Previous
studies suggest the latter, as each peptide binding site on clathrin
characterized to date has a distinct consensus binding motif.10,12,13
However, recent studies have suggested that the binding of peptides
to clathrin may be promiscuous.14,15 Promiscuity of CBM peptides
for multiple sites on clathrin is relevant in the context of host:patho-
gen interactions, as it has previously been observed that viruses con-
tain motifs resembling cellular CBMs that interact with clathrin in
cells. These viral proteins have the ability to sequester clathrin, thus
preventing endocytosis.16,17 In the case of hepatitis D virus (HDV),
which harbours a putative CBM sequence in the C-terminal region of
the large antigen protein (HDAg-L), the presence of the clathrin bind-
ing motif seems essential for production of virus particles.18 If viral
CBM peptides bind only to the clathrin box on NTD it would be pos-
sible to blockade this site using a small molecule inhibitor.19 This
blockade would prevent virus hijacking of clathrin without perturbing
cellular endocytosis, which can proceed when binding to the NTD
“clathrin box” site is disrupted.14 However, if viral CBMs bind multi-
ple sites on NTD with comparable afﬁnities then small molecule inter-
ventions are unlikely to succeed. We thus sought to investigate the
relative afﬁnity of cellular vs viral peptides for clathrin NTD and to
compare their modes of binding. Further, we sought to investigate
the potential degeneracy of clathrin binding that had been suggested
by previous studies.14,15
Here we present high-resolution structures of clathrin NTD
bound to cellular and viral peptide motifs. Surprisingly, in all cases we
observe peptide binding at multiple sites on NTD. We use clathrin-
binding assays and site-directed mutagenesis to qualitatively assess
the binding of these peptide motifs to the different sites on NTD.
Further, we provide the ﬁrst structural characterization of the puta-
tive “fourth” adaptor binding site on clathrin NTD.
2 | RESULTS
2.1 | Cellular clathrin-binding motifs recruit clathrin
more efﬁciently than those from hepatitis D virus
The CBMs from the cellular proteins β2 adaptin (AP2CBM) and
amphiphysin (AmphCBM),9,20 the W box motif of amphiphysin
(Wbox),11,12,20,21 and the C-terminal extensions of HDAg-L from 2 dif-
ferent HDV genotypes containing putative clathrin binding motifs
(HDAg-L1 and HDAg-L2, respectively)16,18 were fused to glutathione
S-transferase (GST) (Figure 1A) and immobilized on glutathione resin
for use in “GST pull-down” experiments to capture clathrin puriﬁed
from pig brain. In addition, to aid comparison with previous biochemi-
cal studies,11 an extended amphiphysin CBM construct (termed
Amph4T1) was used in which the clathrin-binding motif is followed
by the amino acids “LERPHRD” arising from the XhoI cloning site and
subsequent vector-derived nucleotides.22 Consistent with previous
studies,11,12 clathrin was efﬁciently captured by GST fused to
AP2CBM, AmphCBM, Amph4T1 or the amphiphysin Wbox, while it
was not signiﬁcantly captured by GST alone (Figure 1B). Interestingly,
clathrin was not efﬁciently captured by GST fused to either of the
HDAg-L C-terminal extensions tested (Figure 1B).
To facilitate subsequent mutational work the N-terminal domain
(NTD) of bovine clathrin heavy chain (100% amino acid identity to
human clathrin heavy chain NTD), fused to a His6 afﬁnity tag at the
N terminus and to the dimerization domain of NF-κB essential modu-
lator (NEMO)23 at the C terminus, was puriﬁed following expression
in Escherichia coli. This His-NTD-NEMO protein binds GST-AP2CBM
much more efﬁciently than His-NTD lacking the NEMO oligomeriza-
tion domain (Figure S1A). We ascribe this to increased avidity of
binding, as His-NTD-NEMO is capable of oligomerizing at higher con-
centrations whereas His-NTD is monomeric (Figure S1). As observed
using puriﬁed clathrin, recombinant His-NTD-NEMO is efﬁciently
pulled-down by GST-AP2CBM, GST-AmphCBM, GST-Amph4T1 and
GST-Wbox (Figure 1C). His-NTD-NEMO is weakly pulled down by
GST-HDAg-L1, whereas GST-HDAg-L2 does not pull down His-NTD-
NEMO any more efﬁciently than does GST alone.
FIGURE 1 Cellular and viral peptide motifs bind clathrin N-terminal
domain (NTD) to different degrees. A, Glutathione S-transferase
(GST) fusions of clathrin-binding peptides used in this study. Clathrin-
box motifs (CBMs) are aligned in bold. Amph4T1, human
amphiphysin I CBM plus additional residues derived from the
expression vector22; AmphCBM, human amphiphysin I CBM;
AP2CBM, CBM from ﬂexible hinge of β2 adaptin subunit of human
AP2; HDAg-L1, putative CBM from clade I hepatitis D virus large
antigen; HDAg-L2, putative CBM from clade II hepatitis D virus large
antigen; Wbox, human amphiphysin W box binding motif. B, Capture
(“GST pull-down”) of puriﬁed clathrin by GST-tagged clathrin-binding
peptides. Clathrin (input) was incubated with glutathione sepharose
pre-loaded with GST-tagged “bait” proteins. After washing, proteins
bound to the beads (pellet) were subjected to SDS-PAGE and
immunoblotting (WB) using an antibody that recognizes clathrin NTD
(αNTD). C, Capture of His-NTD-NEMO by GST-tagged clathrin
binding peptides. Puriﬁed recombinant His-NTD-NEMO was used in
GST pull-down experiments as in (B).
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2.2 | CBMs of cellular and viral peptides bind
multiple sites on the clathrin NTD
To gain structural insight into the binding of cellular and viral pep-
tides, recombinant NTD was crystallized in the presence of peptides
corresponding to CBMs of β2 adaptin and amphiphysin, the CBM
region of the non-natural Amph4T1 sequence, and the putative
CBMs of HDAg-L1 and HDAg-L2. These co-crystallization experi-
ments were performed using high concentrations (3.4-3.6 mM) of
clathrin-binding peptide to ensure saturation of the peptide binding
sites. The structures of all co-crystals were solved and reﬁned to high
resolution (Table 1) and, surprisingly, in all cases electron density con-
sistent with the presence of peptide bound to NTD could be
observed at more than 1 locus on NTD (Figure 2).
In all the structures presented a peptide could be observed at the
“clathrin box”, lying between blades 1 and 2 of the NTD β-propeller
fold (“clathrin box”, Figure 2). For the cellular peptides (AP2CBMpep,
AmphCBMpep and Amph4T1pep) the binding is similar to that previ-
ously described,10 with the 3 leucine side chains of the CBM LΦxΦ
[DE] consensus sequence occupying the hydrophobic pocket formed
at the groove between the 2 blades. The viral peptides (HDAg-L1pep
and HDAg-L2pep) bound at a similar site on NTD. However, in both
cases only 2 consecutive hydrophobic side chains could be observed
in the hydrophobic pocket (“IL” and “LL” in the cases of HDAg-L1pep
and HDAg-L2pep, respectively). Interestingly, for both HDAg-L1pep
and HDAg-L2pep the residues bound at the clathrin box do not match
predictions based on alignments to the CBM consensus sequence
(Figure 1)16,18: in HDAg-L1pep residues “ILFPA” occupy the positions
corresponding to the LΦxΦ[DE], whereas in HDAg-L2pep the residues
“LLES”, including a C-terminal serine residue that is non-native and
was added to the peptide to aid solubility, occupy the positions equiv-
alent to the ﬁrst 4 residues of the LΦxΦ[DE] consensus.
In addition to binding at the clathrin box, we observed signiﬁcant
binding of the cellular peptides (AP2CBMpep, AmphCBMpep and
Amph4T1pep) at the “arrestin box”, which lies between blades 4 and
5 of the NTD β-propeller fold (“arrestin box”, Figure 2). While all
3 CBM peptides bind in the same general orientation at the arrestin
box (Figure 3), the molecular details of these interactions differ from
the interaction seen between NTD and the extended surface loop of
the arrestin 2 long isoform (arrestin2L).13 Most notably, the direction-
ality of the peptide chain is reversed. The ﬁrst 2 leucine residues of
each CBM (LΦxΦ[DE]) bind in a hydrophobic cavity lined by the side
chains of NTD residues W164, L183, S185, R188, V190, I194, F216,
I231 and V233 plus the peptide backbones of Y184 and S191
(Figure 3B). The position occupied by these 2 peptide leucine side
chains is very similar to that occupied by arrestin2L residues L338
and L335 (residues 5 and 2 of the [LI][LI]GxL arrestin box consensus
motif, respectively) in the complex with NTD, despite the fact that in
the arrestin2L:NTD complex the peptide backbone adopts a vastly
different conformation to accommodate the 2 intervening amino acid
residues (Figure 3C). In the structures presented here the side chain
oxygen atom of NTD residue Q192 forms hydrogen bonds with the
backbone amide protons of these 2 leucine residues (LΦxΦ[DE]) and
the side chain nitrogen atom of Q192 forms a hydrogen bond with
the carbonyl oxygen of the second leucine (LΦxΦ[DE]). While the
electron density was not sufﬁciently well-resolved to allow unambig-
uous modelling in the case of Amph4T1pep, for both the AP2CBMpep
and AmphCBMpep structures the leucine side chain of the third CBM
motif residue (LΦxΦ[DE]) occupies a similar location to the side chain
of arrestin2L residue L334 ([LI][LI]GxL), binding at a hydrophobic sur-
face patch formed by NTD residues I194, F218, H229 and I231. In
the AmphCBMpep structure the side chain of the phenylalanine res-
idue that follows the CBM forms an additional hydrophobic inter-
action with NTD, binding in a hydrophobic cleft formed by side
chains of residues H229, I231 and A247, the aryl side chain region
of K245, and the peptide backbones of residues 245-247. The
HDAg-L2pep peptide could also be observed binding at the arrestin
site, although the interaction was less extensive (Figure 2). The
binding was largely similar to that observed for the cellular CBM
peptides: the side chains of the 2 consecutive leucine residues
bound at the hydrophobic cleft and their backbone atoms inter-
acted with the side chain of Q192 as described above. There was
not strong evidence for the HDAg-L1pep peptide bound at the
arrestin box (Figure 2).
2.3 | Structural identiﬁcation of the “fourth” peptide
binding site on the clathrin NTD
In addition to binding at the clathrin and arrestin boxes, in 3 of the
NTD:peptide co-crystal structures solved (Amph4T1pep, HDAg-L1pep
and HDAg-L2pep) a bound peptide could be observed lying across
the interface between blades 6 and 7 of the NTD β-propeller
(Figure 2). This peptide binding site overlaps with the region identi-
ﬁed in the functional studies of Willox and Royle14 as the fourth
and ﬁnal clathrin adaptor binding site on NTD, and we thus hence-
forth refer to it as the “Royle box” In comparison to surrounding
residues, peptides were generally less well-ordered when bound at
this site than when bound at the clathrin box (Table S1). However,
in all cases a single orientation of the peptide could be modelled
with good stereochemistry and an acceptable ﬁt to electron density
(Figure 4A).
The surface residues bound by peptides at the Royle box are
highly conserved amongst eukaryotic clathrin sequences (Figure 4B).
Binding at the Royle box (Figure 4C) centres on a deep hydrophobic
pocket lying at the interface of blades 6 and 7, formed by the side
chains of NTD residues L5, I7, F9, I282, N296 and V327. In the co-
structure with Amph4T1pep a phenylalanine side chain projects deep
into this pocket while in the HDAg-L1pep and HDAg-L2pep structures
the side chains of a leucine residue and proline residue, respectively,
bind less deeply. In all structures a hydrophobic side chain (leucine in
Amph4T1pep and HDAg-L2pep, isoleucine in HDAg-L1pep) covers a
surface hydrophobic patch formed by the hydrophobic portion of the
R297 side chain and the hydrophobic faces of the peptide bonds
between NTD residues 298-300 on the surface of β-propeller blade
6, and in all structures the backbone carbonyl oxygen of R297 forms
a hydrogen bond with a backbone amide nitrogen of the bound pep-
tide. In each structure 3 consecutive amino acid residues wrap
around the side chain of F9 on the surface of blade 7, forming
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hydrophobic interactions with both faces of the phenylalanine resi-
due’s hydrophobic side chain benzyl group. In addition, in the co-
structures with HDAg-L1pep and Amph4T1pep the backbone carbonyl
oxygen of F9 forms a hydrogen bond with a backbone amide nitro-
gen of the bound peptide, and backbone atom(s) of E11 form hydro-
gen bond(s) with the bound peptide (1 bond in the case of HDAg-
L1pep, 2 in the case of Amph4T1pep). Despite the similar molecular
interactions made between the Royle box and the bound peptides,
we note that the direction of the peptide chain differs between
HDAg-L1pep and Amph4T1pep/HDAg-L2pep (Figure 4C). In addition,
unlike the binding of peptides to the clathrin and arrestin boxes,
where the same side chains of the CBM sequence form key interac-
tions, we note that residues outside the CBM consensus sequence
also form extensive interactions at the Royle box.
To investigate whether the absence of AmphCBMpep binding at
the Royle box arose from an absence of stabilizing residues C-
terminal to the CBM motif, we solved the structure of NTD in com-
plex with a longer sequence containing the human amphiphysin I
CBM (AmphCBMlongpep, sequence ETLLDLDFDPFK; Table S2). As
observed for AmphCBMpep, AmphCBMlongpep bound NTD at the
CBM and arrestin boxes but not at the Royle box (Figure S2).
2.4 | Multiple interaction sites on clathrin NTD
contribute to peptide binding in vitro
A series of His-NTD-NEMO constructs with mutations at each of the
4 peptide binding sites on NTD were generated to probe whether all
the interactions observed in the crystal structures contribute to bind-
ing in a biochemical context, or whether binding can be explained by
a single dominant binding interaction. The mutations introduced at
each site were informed by the crystal structures presented above
and by previous studies (Figure 5A and Table 2). To conﬁrm that
these mutations did not introduce defects in NTD folding, the sec-
ondary structure and thermal stability of these mutants was probed
by circular dichroism (CD) spectroscopy and differential scanning
ﬂuorimetry (DSF, a.k.a. Thermoﬂuor), respectively. The CD spectra of
TABLE 1 Crystallographic data collection and reﬁnement. Values for the highest resolution shell are shown in parentheses
NTD: AP2CBMpep AmphCBMpep Amph4T1pep HDAg-L1pep HDAg-L2pep
Data collection
Space group C2221 C2 C2 C2 C2
Cell dimensions
a, b, c (Å) 108.1, 133.2, 77.9 140.0, 134.1, 78.0 137.8, 131.0, 79.1 136.2, 131.2, 77.9 136.9, 131.2, 78.5
α, β, γ () 90.0, 90.0, 90.0 90.0, 115.1, 90.0 90.0, 116.2, 90.0 90.0, 115.6, 90.0 90.0, 115.9, 90.0
Resolution (Å) 57.1–1.8
(1.81–1.76)
67.1–1.9
(1.93–1.88)
33.6–1.7
(1.74–1.70)
48.4–2.2
(2.21–2.15)
39.2–2.0
(2.00–1.96)
Rmerge 0.053 (1.538) 0.149 (1.092) 0.055 (0.751) 0.101 (0.930) 0.081 (0.581)
< I/σI> 15.8 (1.2) 6.5 (1.3) 13.1 (1.6) 9.6 (1.5) 7.2 (1.5)
CC1/2 1.000 (0.672) 0.993 (0.568) 0.999 (0.564) 0.996 (0.501) 0.996 (0.563)
Completeness (%) 100.0 (100.0) 100.0 (100.0) 98.2 (94.5) 99.7 (99.0) 94.6 (95.9)
Redundancy 7.5 (7.0) 5.1 (4.4) 3.9 (3.4) 4.5 (4.3) 2.5 (2.3)
Reﬁnement
Resolution (Å) 57.1–1.8
(1.81–1.76)
67.1–1.9
(1.93–1.88)
33.6–1.7
(1.74–1.70)
48.4–2.2
(2.21–2.15)
39.2–2.0
(2.01–1.96)
No. of reﬂections (work/free) 52,951/2740 99,868/5291 128,743/6564 63,339/3381 79,976/4224
Rwork/Rfree 0.176/0.205 0.204/0.234 0.158/0.185 0.175/0.207 0.169/0.193
Ramachandran favoured regions (%) 98.7 98.6 98.8 98.2 99.1
Ramachandran outliers (%) 0.0 0.0 0.0 0.0 0.0
No. of atoms
Protein 2836 5845 5796 5634 5634
Glycerol — 18 6 6 6
Peptide ligands 104 268 340 200 240
Water 403 803 1019 437 583
B-factors
Protein 36.1 22.0 26.2 39.8 32.0
Glycerol — 36.5 21.8 32.7 20.9
Peptide ligands 52.4 45.1 48.7 70.2 61.0
Water 53.5 37.8 42.3 45.6 38.2
r.m.s. deviations
Bond lengths (Å) 0.016 0.010 0.014 0.020 0.019
Bond angles () 1.719 1.396 1.619 1.897 1.917
PDB ID 5M5R 5M5S 5M5T 5M5U 5M5V
Abbreviations: NTD, N-terminal domain; PDB, Protein data bank.
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mutants were very similar to that of wild-type NTD (Figure S3), con-
ﬁrming that they had the correct secondary structure composition.
However, DSF showed a number of mutants to have melting tem-
peratures signiﬁcantly lower than the wild-type protein, consistent
with disrupted folding, and these mutants were thus not considered
further (Figure 5B).
A selection of the correctly folded mutants was tested for ability
to bind the cellular clathrin-binding motifs in GST pull-down experi-
ments. Given the modest ability of GST-HDAg-L1 and -L2 to capture
His-NTD-NEMO (Figure 1C) we limited our analysis to the cellular
peptide sequences (GST-AP2CBM, GST-AmphCBM, GST-Amph4T1
and GST-Wbox). Figure 5C shows that mutations at the W box
FIGURE 2 The clathrin-box motifs (CBMs) of cellular and viral proteins bind multiple sites on clathrin N-terminal domain (NTD). Unboxed image
shows the β-propeller fold of clathrin NTD (grey ribbons) with numbers enumerating the 7 β-stranded blades. Spheres represent peptides bound
at the 4 peptide-interaction sites on NTD. Boxed images show CBM-containing peptides (sticks, carbon atoms coloured as follows: AP2CBMpep,
magenta; AmphCBMpep, dark green; Amph4T1pep, yellow; HDAg-L1pep, orange; HDAg-L2pep, light blue) bound at the clathrin box, arrestin box
and Royle box sites on clathrin NTD (grey ribbons). Unbiased FO-FC electron density (3 σ) used to place peptides into the structures is shown as
a green mesh. Selected side chain atoms of clathrin NTD are shown (sticks with grey carbon atoms).
48 MUENZNER ET AL.
(I154Q and I152L + I154Q) severely disrupt the ability of GST-Wbox
to capture His-NTD-NEMO, consistent with previous studies.12 His-
NTD-NEMO with mutations at the clathrin box was less efﬁciently
captured by GST-AP2CBM, the defect being most pronounced for
the Q89A + F91K mutant, but capture of these mutants by GST-
AmphCBM or GST-Amph4T1 was largely unperturbed (Figure 5C).
Similarly, His-NTD-NEMO mutated at the arrestin box (Q192Y) was
captured less efﬁciently by GST-AP2CBM but the capture of this
mutant by GST-AmphCBM or GST-Amph4T1 was not signiﬁcantly
changed (Figure 5C).
To test whether mutation at more than 1 peptide binding site
further reduced capture by cellular CBM peptides, His-NTD-NEMO
constructs with mutations at multiple binding loci were generated.
All these ‘compound mutants’ had CD spectra similar to that of the
wild-type protein (Figure S3) and melting temperatures within 3 K
of the wild-type protein (Figure 5B), consistent with the compound
mutants being well-folded. As shown in Figure 5D, while His-NTD-
NEMO mutated at either the clathrin box (Q89A + F91K) or arrestin
box (Q192Y) can still be captured by GST-AP2CBM, combining the
mutations (Q89A + F91K + Q192Y) reduces the binding to the level
of the GST control. Similarly, His-NTD-NEMO mutated at both the
clathrin and arrestin boxes is captured less efﬁciently by GST-
Amph4T1 than is the wild-type protein or protein with mutants at
either site individually. The decrease in capture of His-NTD-NEMO
with mutated clathrin and arrestin boxes by GST-Amph4T1 is more
pronounced than is the capture of clathrin and Royle box or arrestin
plus Royle box mutants. However, when NTD is mutated at all
3 sites, namely the arrestin, clathrin and Royle boxes, the extent of
capture by GST-Amph4T1 is further decreased and approaches the
levels seen for GST alone. GST-AmphCBM captures His-NTD-NEMO
mutated at both the clathrin and arrestin boxes less efﬁciently than it
does wild-type protein or His-NTD-NEMO with either site mutated
individually. However, none of the His-NTD-NEMO mutations tested
completely abolished binding to GST-AmphCBM.
2.5 | The arrestin motif of AP2 can also bind
multiple sites on clathrin NTD
The hinge region of the assembly polypeptide 2 (AP2) complex β2
adaptin subunit contains 2 overlapping clathrin-binding motifs, a
CBM and an arrestin-box motif (Figure 6A). However, the CBM motif
can bind at the arrestin box in addition to binding at the clathrin box
(Figure 2) and both such interactions contribute to NTD recruitment
(Figure 5D). We therefore sought to compare the NTD binding of the
β2 adaptin arrestin-box motif to that of the β2 adaptin CBM.
Two GST-tagged peptide constructs containing the arrestin-box
motif of β2 adaptin (GST-AP2arrL and GST-AP2arrS) were generated
(Figure 6A). Both contained the β2 adaptin arrestin-box motif
(LLGDL) but, to avoid the potentially confounding issue of a carboxyl-
ate group immediately following the ﬁnal residue of the motif, the
sequences of their C-terminal residues differed: AP2arrS had the sub-
sequent “L” residue of β2 adaptin appended to the arrestin-box motif,
while AP2arrL had the residues “ASS” appended, corresponding to
the residues that follow the LLGDL arrestin-box motif of arrestin2L.13
We compared the ability of GST-AP2CBM, GST-AP2arrS and GST-
AP2arrL to capture either wild-type His-NTD-NEMO or a mutant
(Q98A + F91K + F9W) where the clathrin and Royle boxes, but not
the arrestin box, had been disrupted. Figure 6B shows that GST-
AP2CBM and GST-AP2arrS capture wild-type and Q98A + F91K +
F9W His-NTD-NEMO more efﬁciently than does AP2arrL, suggesting
that the arrestin-box motif (LLGDL) alone binds the arrestin box more
FIGURE 3 Cellular clathrin-box motifs (CBMs) bind in a different
conformation than arrestin2L at the arrestin box. A, The surface of
clathrin N-terminal domain (NTD) is shown (grey) oriented as in
Figure 2 (left) and rotated by 90 around the horizontal axis (right).
The AmphCBMpep peptide bound at the arrestin box is shown as
coloured spheres. B, Close-up view of cellular CBM-containing
peptides bound at the arrestin box. Peptides are shown as sticks
coloured as in Figure 2. The surface of clathrin NTD is shown,
coloured from high (green) to low (white) surface residue
hydrophobicity, with outlines of selected surface side chains shown
in grey. Bound AP2CBMpep residues are numbered by their position
in the LΦxΦ[DE] CBM consensus sequence. C, The extended surface
loop of arrestin 2 long isoform (arrestin2L) bound at the arrestin box
(PDB 3GD1).13 NTD is shown as in (B) and arrestin2L residues 332-
340 are shown as sticks with cyan carbon atoms. Note that in (B) the
direction of the bound peptides is right (N terminus) to left
(C terminus), whereas in (C) the peptide chain between residues
L334-L338 runs in the opposite direction.
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weakly than does the CBM or an extended arrestin motif (LLGDLL)
containing the ﬁrst 2 residues of the overlapping CBM. However,
these experiments also show that GST-AP2arrL and GST-AP2arrS
capture wild-type His-NTD-NEMO much more efﬁciently than they
do the Q98A + F91K + F9W mutant, consistent with the β2 adaptin
arrestin-box motif binding to either the clathrin or Royle boxes in
addition to the arrestin box.
3 | DISCUSSION
This study presents the structure of the clathrin heavy chain NTD
solved in the presence of cellular and viral clathrin-binding peptides.
In all cases, we observe that these peptides bind promiscuously to
more than one site on the clathrin NTD surface. This differs from pre-
vious high-resolution structural characterizations of peptide binding
FIGURE 4 Localization and characterization of the fourth peptide binding site on clathrin N-terminal domain (NTD): The Royle box. A,
Amph4T1pep (left), HDAg-L1pep (middle) and HDAg-L2pep (right) peptides bound at the Royle box in feature-enhanced maps
24 calculated using
the ﬁnal reﬁned model (2σ, magenta). For clarity, maps are shown only within 2 Å of the bound peptides. Peptides are shown as sticks, coloured
as in Figure 2, and clathrin NTD is shown as a grey surface. B, The surface of clathrin NTD, coloured by amino acid conservation from
conserved (magenta) to variable (blue), is shown oriented as in Figure 2 (left) and rotated by 90 around the vertical axis (right). The Amph4T1pep
peptide bound at a conserved surface patch between NTD β-propeller blades 6 and 7 (which we term the Royle box) is shown as sticks with
yellow carbon atoms. C, Close-up view of cellular and virus peptides bound at the Royle box. Peptides are shown as sticks coloured as in
Figure 2. The surface of clathrin NTD is shown, coloured from high (green) to low (white) surface residue hydrophobicity, with outlines of
selected surface side chains shown in grey. A hydrophobic NTD surface pocket that is occupied by hydrophobic residues of all three peptides is
marked by a dotted line. The peptide sequences used for co-crystallization are structurally aligned at the bottom of the panel. The directionality
of the bound peptides is indicated. Residues that could be conﬁdently modelled in the structures are highlighted and residues that form side
chain interactions with NTD surface pockets are printed in bold type. D, Cellular and viral peptides bind near NTD residues functionally
implicated in clathrin-mediated endocytosis. The surface of NTD (grey) is oriented as in the right image of (A) with residues mutated by Willox
and Royle14 (light and dark purple) or in this study (pink) highlighted. The Amph4T1pep peptide is shown as spheres. Inset shows the
Amph4T1pep peptide (sticks with yellow carbon atoms) bound to NTD (grey, ribbon with selected side chains shown as sticks). The carbon
atoms of residues substituted in clathrin mutants that disrupt transferrin uptake,14 a proxy for clathrin-mediated endocytosis, are dark purple
while those of residues where substitution does not affect transferrin uptake are light purple. The side chain of F9, mutated in this study, is
coloured bright pink.
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to clathrin NTD: structures of NTD solved in the presence of β3
adaptin and β-arrestin 2 CBMs showed binding only at the clathrin
box,10 only the W box site is occupied in the structure solved in the
presence of a peptide derived from the “second” (PWDLW) clathrin-
binding motif of amphiphysin,12 and the structure of NTD in complex
with a long splice form arrestin 2 (arrestin2L) shows binding of 2 dif-
ferent peptide motifs at the clathrin and arrestin box sites. We
observe that the CBMs of β2 adaptin, amphiphysin and HDAg-L2
bind to both the clathrin and arrestin box sites. Further, we provide
the ﬁrst structural characterization of the putative fourth and ﬁnal
peptide binding site on clathrin NTD,14 which we term the Royle box.
3.1 | The arrestin box binds linear CBM peptides
The structure of arrestin2L bound to clathrin NTD revealed two dif-
ferent peptide epitopes bound at the clathrin and arrestin boxes.13
FIGURE 5 Mutation at single or multiple sites on clathrin N-terminal domain (NTD) disrupts binding to peptide motifs. A, Ribbon representation
of NTD (grey) showing the location of residues that were mutated on their own or in combination to disrupt peptide binding at the clathrin box
(blue), arrestin box (green), W box (orange) and Royle box (purple). B, Thermal stability of single- or multiple-site mutations of NTD as
determined by differential scanning ﬂuorimetry. The melting temperatures (TM) of mutants relative to that of wild-type His-NTD are shown
(error bars represent the standard deviation of measurement in triplicate). Mutations that perturb the TM by more than 3 K (dotted line) were
not considered further. C and D, Capture of NTD mutants by glutathione S-transferase (GST)-tagged clathrin-binding peptides. Puriﬁed
recombinant wild-type or mutant His-NTD-NEMO was incubated with glutathione sepharose pre-loaded with GST-tagged “bait” proteins. After
washing, proteins bound to the beads (pellet) were subjected to SDS-PAGE and immunoblotting (WB) using an antibody that recognizes clathrin
NTD (αNTD).
TABLE 2 Clathrin heavy chain N-terminal domain mutations
Mutation Site Reference
Q89M Clathrin box 25
F91A Clathrin box 25
Q89A + F91K Clathrin box This study
Q192Y Arrestin box This study
W164E Arrestin box 13
L183K + Q192A Arrestin box This study
Q152L W box 12
I154Q W box 12
Q152L + I154Q W box 14
F9E Royle box This study
F9W Royle box This study
E11K Royle box 14
Q14D + Q16M + N17S Royle box 14
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The epitope bound at the arrestin box comprised an 8 amino acid
surface loop that connects 2 adjacent anti-parallel beta strands of
arrestin2L: this loop thus necessarily forms a relatively tight turn at
its apex. The key molecular interactions are formed by three leucine
side chains (L334, L335 and L338) from the arrestin2L loop that are
adjacent in space (Figure 3C), but not consecutive in sequence, and
biochemical studies deﬁned the consensus binding sequence of this
loop as [LI][LI]GxL.13
The structures presented here show that CBM peptides, match-
ing the LΦxΦ[DE] CBM consensus sequence, also bind NTD at the
arrestin box (Figure 2) and that this interaction contributes to binding
in vitro (Figure 5). Interestingly, the molecular determinants of bind-
ing are conserved between the arrestin2L loop and the CBM pep-
tides: hydrophobic leucine or isoleucine side chains bind the groove
between NTD β-propeller blades 4 and 5, occupying roughly equiva-
lent spatial positions (Figure 3). However, the peptide backbone
topology differs substantially as does the spacing between the crucial
leucine/isoleucine residues. We therefore propose that the consensus
sequence for binding at the arrestin box is likely to be context-
dependent. In the case of arrestin2L, the amino acids that mediate
binding are partly determined by the constrained nature of the sur-
face loop. However, when presented as linear motifs, as is likely to
be the biological context of the β2 adaptin, epsin 1 and amphiphysin
CBM epitopes,3,4,9,21,26 peptides that conform to the LΦxΦ[DE] CBM
consensus sequence can also bind the arrestin box.
Our structural characterization of CBM peptides bound promis-
cuously at multiple sites on clathrin NTD is largely consistent with a
recent biophysical study showing promiscuous binding of long
peptides derived from β2 adaptin and AP180 at the clathrin, arrestin
and W boxes of NTD.15 However, while the long β2 adaptin peptide
used in the biophysical study harboured both CBM (LLNLD) and
arrestin2L (LLGDL) consensus sequences, the β2 adaptin CBM
(AP2CBM) peptide used here contains only a CBM. We observe that
combining mutations at the arrestin and clathrin boxes completely
abolishes the ability of the AP2CBM to capture NTD in GST pull-
down assays, conﬁrming that CBM peptides bind promiscuously to
both sites. Unlike the previous biophysical study, peptide binding at
the W box was not observed in any of the crystal structures pre-
sented here. We ascribe this to the use of much longer peptides in
the biophysical study that may harbour additional, non-canonical W
box binding motifs.
Given the similar molecular determinants of linear peptide bind-
ing at the clathrin and arrestin boxes, it is perhaps surprising that
binding at the arrestin box was not observed in the previous co-
crystallization study that used the β3 adaptin and β-arrestin 2 CBM
peptides.10 However, we note the prior study used a lower molar
excess of peptide (4-fold excess versus 7- to 10-fold excess used
here). Further, the extended cryo-protection protocols employed in
the prior study, using cryo-preservative solutions without added pep-
tide, may have facilitated dissociation of bound peptides from lower-
afﬁnity sites and thus removed evidence of their binding.
3.2 | Structural characterization of the Royle box
As observed at the arrestin box (above), the molecular determinants
of binding at the Royle box are conserved despite a difference in
peptide orientation observed for the bound HDAg-L1pep peptide vs
the bound HDAg-L2pep and Amph4T1pep peptides. However, unlike
at the arrestin box, residues that form the molecular
interactions at the Royle box do not correspond to those conserved
in the LΦxΦ[DE] consensus CBM sequence and we note that several
peptides containing a CBM sequence (AP2CBMpep, AmphCBMpep
and AmphCBMlongpep) do not bind at the Royle box (Figures 2 and
S2). Together, this suggests that a distinct consensus sequence med-
iates binding of cellular proteins at the Royle box. While the HDAg-
L1pep and HDAg-L2pep peptides that bind the site occur naturally in
hepatitis D virus, the Amph4T1pep sequence used in this study con-
tains amino acids corresponding to those introduced when cloning
the amphiphysin CBM into the pGEX-4T1 vector.22 Attempts to
deﬁne a consensus sequence and screen in silico for genuine cellular
binding peptide motifs were unsuccessful due to the degeneracy of
the peptide sequences bound in our structures. Identiﬁcation of the
Royle box consensus binding motif therefore awaits experimental
elucidation.
In accordance with previous functional studies,14 all three struc-
tures of peptides bound at the Royle box presented here show bind-
ing at a conserved surface patch that lies between blades 6 and 7 of
the NTD β-propeller (Figure 4B). The bound peptides all wrap around
the hydrophobic side chain of NTD residue F9, which also lines the
hydrophobic pocket central to the interaction of peptides at the
Royle box (Figures 4C and 4D). Mutation of F9 to the bulkier residue
tryptophan does not destabilize NTD (Figure 5B) but is able to dimin-
ish binding to GST-Amph4T1 when combined with mutations at the
FIGURE 6 The overlapping β2 adaptin arrestin-box and clathrin-box
motifs both bind multiple sites on clathrin N-terminal domain
(NTD). A, Glutathione S-transferase (GST) fusions of the clathrin-box
motif (GST-AP2CBM) and arrestin-binding motif (GST-AP2arrS and
GST-AP2arrL) from the hinge region of β2 adaptin, the arrestin-box
motif constructs having either the next residue of β2 adaptin (“L”,
GST-AP2arrS) or the sequence that follows the LLGDL motif of
arrestin2L (“ASS”, GST-AP2arrL) appended at their C termini. B,
Capture of wild-type NTD or a mutant with disrupted clathrin and
Royle boxes (Q89A + F91K + F9W) by GST-tagged β2 adaptin
clathrin-binding motifs. Puriﬁed recombinant wild-type or mutant
His-NTD-NEMO was incubated with glutathione sepharose pre-
loaded with GST-tagged “bait” proteins. After washing, proteins
bound to the beads (pellet) were subjected to SDS-PAGE and
immunoblotting (WB) using an antibody that recognizes clathrin
NTD (αNTD).
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arrestin and clathrin boxes, conﬁrming the importance of F9 for pep-
tide binding. Previous functional experiments showed that 2 sets of
mutations at the Royle box, E11K and Q14D + Q16M + N17S
(Figure 4D), were sufﬁcient to prevent transferrin uptake (a readout
for clathrin-mediated endocytosis) when combined with mutations at
the clathrin, arrestin and W boxes. While the side chain of E11 does
not interact directly with bound peptides, in the HDAg-L1pep and
Amph4T1pep structures E11 backbone atoms form hydrogen bonds
with the bound peptide. Further, we ﬁnd that the E11K mutation
reduces the TM of NTD by 3.7 K, consistent with some destabiliza-
tion of the protein fold. We propose that destabilization of the local
fold in the E11K NTD mutant prevents its binding to Royle box bind-
ing epitopes in cells. Residues of the second disrupting mutation,
Q14D + Q16M + N17S, do not directly contact peptides bound at
the Royle box in our structures but are in close proximity to peptide-
binding residues (Figure 4D). Residue Q14 lies on the same short
stretch of β-sheet as E11, the side chains of these two residues form-
ing a hydrogen bond, while Q16 and N17 lie on the surface of a short
α-helix immediately following Q14 (Figure 4D). The thermal stability
of puriﬁed Q14D + Q16M + N17S NTD is slightly higher than the
wild-type NTD (Figure 5B), which may indicate perturbation of the
protein fold in the vicinity of bound peptide. Alternatively, one
could speculate that the N-terminal residues of a bona ﬁde cellular
Royle box binding motif could bind the Royle box in an extended
conformation and interact with these residues, although identiﬁca-
tion of such a motif remains elusive. A third set of mutations at the
Royle box, N296A + R297E, did not seem to affect the ability of
NTD to promote transferrin uptake,14 yet both residues are in close
proximity to the peptide bound at the Royle box in the structures
presented here. It is possible that the precise nature of substitutions
introduced at residues N296 and R297 led to sustained transferrin
uptake: N296 lines the rim of the deep hydrophobic pocket and its
mutation to alanine, conferring a short hydrophobic side chain,
should not prevent binding. Similarly, interactions with R297 are
mediated primarily by the backbone and hydrophobic Cβ and Cγ side
chain atoms, all of which would remain when the residue was
mutated to glutamate.
3.3 | HDV peptides bind the same sites on NTD as
cellular peptides
Previous studies showed that GST fused to residues 198-210 of
HDAg-L, comprising the majority of the HDAg-L C-terminal extension
that is expressed following editing of the HDV RNA antigenome,27 is
capable of capturing clathrin heavy chain from cell lysates.16 Further,
mutation of a putative CBM sequence in this C-terminal extension
prevented both co-immunoprecipitation of clathrin heavy chain from
transfected cells and the formation of virus-like particles (VLP).18 It
was therefore concluded that HDAg-L is a novel viral clathrin
adaptor-like protein.16,18 We sought to extend this observation by
probing whether cellular and HDAg-L peptides bind the same or dif-
ferent sites on clathrin NTD, with a view to developing small-
molecule inhibitors of the HDAg-L interaction with clathrin NTD that
would restrict HDV replication.
Our structural results show that peptides containing the
putative CBMs of two distinct HDAg-L sequences (HDAg-L1pep
and HDAg-L2pep) bind the same sites on clathrin NTD as cellular
CBM peptides, binding at the clathrin box, the Royle box and (for
HDAg-L2pep) the arrestin box (Figure 2). However, GST pull-down
experiments performed with either puriﬁed clathrin or an oligo-
merized form of the NTD (His-NTD-NEMO) showed that these
viral peptides capture NTD much less efﬁciently than do cellular
CBM epitopes (Figure 1B,C). Previous cell-based studies showed
that mutation of HDAg-L1 L199 to alanine severely reduced VLP
production and clathrin co-immunoprecipitation.18 This is consist-
ent with our structure, as L199 forms extensive hydrophobic con-
tacts at both the Royle and clathrin boxes (Figure 2). HDAg-L1
mutation D203A also diminished VLP production and co-
immunoprecipitation with clathrin, but in the structures pre-
sented here this residue is consistently disordered. It is thus
unclear whether this mutation directly affects binding of HDAg-L
to clathrin or has some secondary effect. Previous biochemical
studies of HDAg-L peptides binding to puriﬁed NTD also sug-
gested that both L199 and D203 are important for the interac-
tion.16,28 However, these experiments should be viewed with
caution as they utilized an extremely short NTD construct (resi-
dues 1-107) that not only lacks both the Royle and arrestin box
sites but also spans only the ﬁrst two blades of the NTD
β-propeller and is thus highly unlikely to be correctly folded.
Taken together, our results conﬁrm that the putative CBM pep-
tides from HDAg-L can directly bind clathrin NTD, but do so
weakly. It is therefore unclear whether these viral CBM-like epi-
topes directly promote recruitment of clathrin heavy chain
in vivo or whether they act synergistically with other clathrin-
adaptor proteins.
3.4 | Degeneracy of clathrin-binding peptide motifs
Our structural (Figure 2) and biochemical (Figure 5) studies show
that 2 distinct sequence motifs can bind the arrestin box of NTD:
the arrestin-box motif ([LI][LI]GxL) and the CBM (LΦxΦ[DE]). Fur-
ther, Figure 6B shows that, when presented as linear peptides,
either the β2 adaptin CBM motif (GST-AP2CBM) or an extended
arrestin-box motif (GST-AP2arrS, where the arrestin-box motif is
followed by a leucine residue) bind the arrestin box more strongly
than does the arrestin-box motif alone (GST-AP2arrL). This experi-
ment also suggests that the β2 adaptin arrestin-box motif is capa-
ble of binding the clathrin or Royle boxes (compare capture of
wild-type vs Q98A + F91K + F9W His-NTD-NEMO), despite this
arrestin-box motif (LLGDL) not conforming to the CBM consensus
sequence. Similarly, we note that the sequences capable of bind-
ing the Royle box in crystallo are also rather degenerate, preclud-
ing the identiﬁcation of a consensus binding sequence. Together,
this suggests that the model of “1 consensus binding motif per
peptide-binding site on clathrin NTD” might need revisiting, as the
binding of these short peptides to the NTD surface is degenerate
and may depend on the structural context in which the peptides
are presented.
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3.5 | Dynamics of association between clathrin
terminal domain and adaptor peptides in coated pits
The results presented in this study underline the dynamic nature of
clathrin:adaptor interactions and suggest that each clathrin terminal
domain is capable of simultaneously binding multiple adaptors, even
those containing only CBM (LΦxΦ[DE]) or arrestin-box ([LI][LI]GxL)
motifs. Individually, these interactions are of low afﬁnity.4,15 Proteins
typically bind to both speciﬁc and non-speciﬁc sites with similar asso-
ciation rates (kon), with differential afﬁnity conferred by differing rates
of dissociation (koff).
29 Weak bimolecular interactions in the micromo-
lar afﬁnity range, such as those between clathrin and its adaptors,
typically correspond to dissociation rates of about 1 second or a half-
time of dissociation of ~0.7 seconds.29 This is signiﬁcantly shorter
than the timescale of productive clathrin-coated pit assembly and
deformation, which occurs over the course of ~90 seconds.30 Thus,
we would expect adaptors to display rapid cycles of binding to and
dissociation from individual binding sites on clathrin, allowing recruit-
ment of a multitude of different adaptor molecules to any given cla-
thrin terminal domain. It is also possible that plasticity in clathrin
motif binding allows individual adaptors harbouring multiple clathrin-
interaction motifs, such as epsin,22 to bind multiple sites on the cla-
thrin N-terminal domain simultaneously, thereby increasing their
apparent afﬁnity. However, as we are not yet able to deﬁne a con-
sensus binding sequence for the Royle box, and considering the
degenerate sequence requirements for binding at the clathrin or
arrestin boxes, it is unclear how frequently clathrin adaptors might be
able to employ such a mode of binding.
In summary, we have shown that cellular CBM peptides bind
degenerately to multiple sites on clathrin, we deﬁne a set of NTD
mutations at each of the 4 peptide binding sites that do not dis-
rupt the NTD fold, and show in biochemical assays that multiple
sites contribute to binding of NTD by cellular clathrin-binding
peptides. In addition, we ﬁnd that viral CBM peptides bind the
same sites on NTD as cellular peptides, albeit much more weakly.
Finally, we present the ﬁrst structural characterization of the
Royle box, the fourth and ﬁnal functional peptide binding site on
the clathrin NTD.
4 | MATERIALS AND METHODS
4.1 | Constructs and mutagenesis
Wild-type bovine clathrin heavy chain N-terminal domain (1-363)
(NTD) with an N-terminal glutathione S-transferase (GST) puriﬁcation
tag and thrombin cleavage site was used as described previously.11
For binding assays, an oligomeric construct was designed by fusing
clathrin NTD (1-363) to the NF-κB essential modulator (NEMO) oli-
gomerization domain (246-365) and cloning into pET-28(a) to add an
N-terminal His6 puriﬁcation tag (His-NTD-NEMO). Mutated con-
structs encoding His-NTD-NEMO with single amino acid substitu-
tions at residues F9, E11, Q14, Q16, N17, Q89, F91, Q152, I154,
W164, L183 and Q192 were generated by QuikChange site-directed
mutagenesis (Agilent) and introduction of the desired mutations was
conﬁrmed by Sanger sequencing. Clathrin-binding motifs were cloned
into pOPT3G,31 encoding GST followed by a human rhinovirus 3C
protease cleavage site and the peptide of interest, by ligation of
phosphorylated annealed oligonucleotide primers as follows: GST-
HDAg-L1, residues 195-214 of hepatitis D virus large antigen
(HDAg-L) clade I (UniProt P0C6L6); GST-HDAg-L2, residues 194-213
of HDAg-L clade II (UniProt A4ZNG7); GST-AP2CBM, residues 629-
640 of the β2 adaptin subunit of human AP2 (UniProt P63010); GST-
Wbox, residues 379-388 of human amphiphysin I (UniProt P49418);
GST-AmphCBM, residues 349-358 of human amphiphysin I (Uniprot
P49418). Two constructs containing the arrestin-box motif (LLGDL)
of the β2 adaptin subunit of human AP2 (UniProt P63010) were gen-
erated the in the same manner: GST-AP2arrS, residues 623-632 and
GST-AP2arrL, residues 623-631 followed by the sequence “ASS” that
corresponds to the residues C-terminal to the LLGDL arrestin-box
motif of arrestin2L.13 An additional construct (GST-Amph4T1) encod-
ing residues 349-356 of rat amphiphysin I (UniProt O08838; rat and
human amphiphysin I residues 349-356 are identical), inserted into
pGEX-4T1 after EcoRI/XhoI digestion and thus encoding 7 additional
amino acids (LERPHRD) C-terminal to the amphiphysin sequence,
was described previously.22
4.2 | Protein expression and puriﬁcation
A clathrin-coated vesicle fraction was isolated from pig brains
essentially as described.32 Coat proteins were stripped from the
vesicles33 and clathrin was puriﬁed from the coat protein mixture
by gel ﬁltration in 0.5 M Tris pH 7.0, 1 mM DTT (Superose 6, GE
Healthcare), dialyzed into 10 mM Tris pH 8.0 and stored at 4C.
All other proteins were expressed in E. coli strains BL21(DE3)
pLysS (GST-tagged constructs) or B834(DE3) (wild-type and mutant
His-NTD-NEMO). Bacteria were grown in 2×TY medium with appropri-
ate selection antibiotics to an optical density (OD)600 of 0.8-1.0, the
temperature was reduced to 22C and protein expression was induced
by addition of 0.2 mM isopropyl β-D-thiogalactopyranoside. After
12-18 h cells were harvested by centrifugation (6000 × g, 15 min, 4C)
and stored at −80C.
Bacterial pellets containing GST-NTD were resuspended in lysis
buffer (20 mM Tris pH 7.5, 200 mM NaCl, 0.05% TWEEN-20,
0.5 mM MgCl2, 1.4 mM β-mercaptoethanol) supplemented with
200-400 U bovine DNase I (Sigma) and 200 μL ethylenediaminete-
traacetic acid (EDTA)-free protease inhibitor cocktail (Sigma). Cells
were lysed at 24 kpsi using a cell disruptor (Constant Systems) and
the lysate was cleared by centrifugation (40 000g, 30 min, 4C).
Cleared lysate was incubated with glutathione Sepharose 4B
(GE Healthcare) for 60 minutes at 4C, the beads were washed
(20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT), equilibrated in
thrombin cleavage buffer (20 mM Tris pH 7.5, 200 mM NaCl, 1 mM
CaCl2), and the GST tag removed by overnight incubation at room
temperature with thrombin (125 U, Serva). Following incubation
with fresh glutathione resin to capture liberated GST and uncleaved
GST-NTD fusion, NTD was further puriﬁed using a HiLoad Superdex
200 size exclusion chromatography column (GE Healthcare) equili-
brated in 10 mM Tris pH 7.5, 50 mM NaCl, 4 mM DTT. Following
concentration, small aliquots (20-100 μL) of puriﬁed NTD were
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snap-frozen in liquid nitrogen and stored at −80C.34 For other
GST-tagged proteins, cell pellets were resuspended in lysis buffer
(20 mM HEPES pH 7.5, 300 mM NaCl, 0.05% TWEEN-20, 0.5 mM
MgCl2, 1.4 mM β-mercaptoethanol) supplemented with DNase I and
protease inhibitors as above. Cells were lysed, and lysates were clar-
iﬁed and incubated with glutathione resin as above. The glutathione
resin was washed (20 mM HEPES pH 7.5, 300 mM NaCl, 1 mM
DTT) and bound proteins were eluted using wash buffer supplemen-
ted with 25 mM reduced glutathione. Following size exclusion chro-
matography using HiLoad Superdex 75 or 200 columns
(GE Healthcare) equilibrated in 20 mM HEPES pH 7.5, 200 mM
NaCl, 1 mM DTT, fusion proteins were mixed 1:1 with 100% (v/v)
glycerol and stored at −20C.
For wild-type and mutant His-NTD-NEMO, cell pellets were
resuspended in lysis buffer (20 mM Tris pH 7.5, 500 mM NaCl,
0.05% TWEEN-20, 0.5 mM MgCl2, 1.4 mM β-mercaptoethanol)
supplemented with 2-20 mg hen egg white lysozyme (Sigma),
400 U bovine DNase I (Sigma) and 200 μL EDTA-free protease
inhibitor cocktail (Sigma). The cells were lysed and the lysate clari-
ﬁed as described above. The cleared lysate was applied to a 1 mL
HisTrap excel Ni afﬁnity column (GE Healthcare), the column was
washed (20 mM Tris pH 7.5, 500 mM NaCl, 12.5 mM imidazole
pH 7.5) and the protein eluted (20 mM Tris pH 7.5, 500 mM
NaCl, 250 mM imidazole pH 7.5). The Ni afﬁnity column eluate
was injected onto a HiLoad Superdex 200 column (GE Healthcare)
equilibrated in 20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT and
eluted in distinct peaks, which were collected and concentrated
separately to yield His-NTD-NEMO and His-NTD (Figure S1),
which were both were snap-frozen in liquid nitrogen as described
above.
4.3 | Crystallization, data collection, structure
determination and analysis
Crystals were grown at 20C by sitting drop vapour diffusion. Cla-
thrin NTD (1-363) was co-crystallized in complex with the following
peptides (peptide sequences are listed with residues not present in
the GST-tagged constructs underlined): Amph4T1pep (ETLLDLDFLE);
AmphCBMpep (ETLLDLDFDP); AP2CBMpep (CGDLLNLDLG); HDAg-
L1pep (SDILFPADS); HDAg-L2pep (SPRLPLLES); AmphCBMlongpep
(ETLLDLDFDPFK). Peptides were purchased from Genscript
(Amph4T1pep, AmphCBMpep and AmphCBMlongpep) or Designer Bio-
science (AP2CBMpep, HDAg-L1pep and HDAg-L2pep). All peptides
were prepared as 10 mM stock solutions in 10 mM Tris pH 7.5,
50 mM NaCl, 4 mM DTT and stored at −20C. NTD was mixed 2:1
with peptide to give ﬁnal concentrations of 14 mg/mL NTD and
3.4 mM peptide for all crystallization experiments except NTD:
HDAg-L2pep, where 20 mg/mL NTD and 3.6 mM peptide was used.
Crystals for structure determination were obtained under the follow-
ing conditions (P and R indicate peptide:protein and reservoir
volumes in sitting drops, respectively): NTD:Amph4T1pep, 1 μL P plus
1 μL R equilibrated against a 200 μL reservoir of 1.1 M sodium malo-
nate pH 8.0 (Hampton Research); NTD:AmphCBMpep, 1 μL P plus
2 μL R equilibrated against a 200 μL reservoir of 0.85 M sodium
malonate pH 7.5; NTD:AP2CBMpep, 1 μL P plus 2 μL R equilibrated
against a 200 μL reservoir of 0.94 M sodium malonate pH 6.7; NTD:
HDAg-L1pep, 400 nL P plus 200 nL R equilibrated against a 80 μL
reservoir of 1.21 M sodium malonate pH 7.0; NTD:HDAg-L2pep,
200 nL P plus 400 nL R equilibrated against a 80 μL reservoir of
1.75 M sodium malonate pH 7.0; NTD:AmphCBMlongpep, 1 μL P plus
2 μL R (1.04 M sodium malonate pH 7.1, 0.2 M sodium perchlorate
[Jena Bioscience]) equilibrated against a 200 μL reservoir of 1.15 M
sodium malonate pH 7.1. All crystals were cryoprotected by rapid
transfer into a drop comprising 55% reservoir solution, 25% (v/v)
glycerol and 20% (v/v) 10 mM peptide stock solution, the peptide
being added to prevent dissociation from NTD of bound peptides.
Crystals were then immediately ﬂash-cooled in liquid nitrogen and
stored in liquid nitrogen.
Diffraction data were recorded at 100 K on Diamond Light
Source beamlines I02 (NTD:HDAg-L1pep, NTD:HDAg-L2pep and NTD:
AmphCBMlongpep) and I04-1 (NTD:Amph4T1pep, NTD:AmphCBMpep
and NTD:AP2CBMpep). Data were processed using XDS, XSCALE and
Aimless (NTD:Amph4T1pep, NTD:HDAg-L1pep and NTD:AmphCBM-
longpep), or DIALS and Aimless (NTD:AmphCBMpep and NTD:
AP2CBMpep), as implemented by the xia2 automated processing
pipeline,35–41 or using iMOSFLM42 and Aimless interactively (NTD:
HDAg-L2pep). The structures of the NTD:HDAg-L1pep, NTD:HDAg-
L2pep, NTD:Amph4T1pep, NTD:AmphCBMpep and NTD:AmphCBM-
longpep complexes were solved by isomorphous replacement in
REFMAC543,44 using a high-resolution ligand-free model of NTD
(PDB 1C9I)10 as a starting model. The structure of the NTD:
AP2CBMpep complex was solved by molecular replacement with a
single chain of NTD (PDB 1C9I, chain A) as a search model using
Phaser.45 Manual model building was performed using COOT46 and
the models were reﬁned using REFMAC5. In all structures, the pep-
tides were modelled after initial improvement of the peptide-free
structure. The geometric quality of the models was improved by con-
sulting the validation tools in COOT as well as the programmes Mol-
Probity47 and WHAT_CHECK.48 Structure factors and ﬁnal reﬁned
models have been deposited with the Protein Data Bank as listed in
Table 1 and Table S2. Feature-enhanced maps, which have reduced
model bias and optimized scaling to ease comparison of strong and
weak features, were calculated using phenix.fem.24,49 Evolutionary
conservation of amino acids was estimated using ConSurf50 with
default parameters and chain A of the reﬁned NTD:Amph4T1pep
structure as an input model. PyMOL (Schrodinger) was used to gener-
ate molecular graphics and ﬁgures were assembled using Inkscape
(https://inkscape.org/).
4.4 | Capture (GST pull-down) assays and
immunoblotting
All steps of the clathrin or His-NTD-NEMO capture assays were per-
formed at 4C using a previously published protocol11 adapted to
enable detection of the very weak interactions investigated in this
work. A total of 40 μL of glutathione sepharose 4B beads
(GE Healthcare) pre-equilibrated in assay buffer (25 mM HEPES-
KOH, 125 mM potassium acetate, 5 mM magnesium acetate, 2 mM
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EDTA, 2 mM EGTA, 1 mM DTT, pH 7.2) were incubated for 2 h with
20 μg (for puriﬁed clathrin pull-down experiments) or 500 μg (for
recombinant NTD pull-downs) of GST or GST fusion proteins in assay
buffer to a ﬁnal volume of 400 μL. Non-immobilized bait protein was
removed following centrifugation (10 000g, 2 min) and the resin was
washed thrice with assay buffer. The protein-loaded resin was then
incubated with 300 μL of 0.1 mg/mL His-NTD-NEMO or His-NTD,
or 0.4 μM puriﬁed clathrin, for 2 hours. Following centrifugation,
supernatants containing uncaptured protein were retained for analy-
sis and the resins were washed 4× with phosphate-buffered saline.
After the ﬁnal wash, the resin pellet was resuspended in 80 μL SDS-
PAGE buffer and the samples were eluted by boiling for 5 min at
95C. Input and supernatant samples were prepared in SDS-PAGE
buffer. Samples (0.33% of the prey input samples, 11.25% of the eluted
pellet samples, 0.6% of the supernatant kept after the prey incubation)
were separated by SDS-PAGE and transferred to nitrocellulose mem-
branes before immunoblotting using a mouse anti-clathrin N-terminal
domain primary antibody (ab11221, Abcam) and ﬂuorescently labelled
goat anti-mouse secondary antibody (925-32210, LI-COR). Dried mem-
branes were visualized using an Odyssey scanner (LI-COR).
4.5 | Biophysical assays: CD spectroscopy,
differential scanning ﬂuorimetry and multi-angle light
scattering
Circular dichroism spectra were recorded on a Jasco J-810 spectro-
polarimeter at 20C. Protein samples were diluted to 1 mg/mL in
50 mM phosphate buffer, pH 7.4. A total of 8 spectra per sample
were recorded (50 nm/min, 1 nm bandwidth, 260-190 nm), averaged,
and smoothed (Savitzky and Golay method, second order smoothing,
5 nm sliding window) using PRISM 5 (GRAPHPAD Software).
Differential scanning ﬂuorimetry experiments to determine the
melting temperature (TM) of wild-type or mutant His-NTD were per-
formed using a MiniOpticon real-time PCR system (BioRad) with 10×
SYPRO Orange dye (Molecular Probes) or Viia7 real-time PCR system
(Applied Biosystems) using 1× Protein Thermal Shift dye (Applied
Biosystems). Multiple experiments conﬁrmed that the difference
between the TM of wild-type His-NTD and mutants (TM[wt]-TM[mu-
tant]) is measured consistently using either platform. In all experi-
ments, assay buffer (20 mM HEPES-KOH, 120 mM potassium
acetate, pH 7.5) was mixed with dye stock solution and protein solu-
tion in an 8:1:1 ratio, to give 10 ng protein in a ﬁnal volume of 50 μL
(MiniOpticon) or 2 ng protein in a ﬁnal volume of 20 μL (Viia7). Sam-
ples (measured in triplicate) were heated from 20C to 90C at 1 K/
minutes (MiniOpticon) or 25 to 95C at 1 K/20 seconds (Viia7) and
ﬂuorescence was monitored at 1 K increments. Curve ﬁtting, melting
temperature calculations and plotting were performed using MATLAB
(MathWorks).
Multi-angle light scattering (MALS) experiments51 were per-
formed at 22C using a Superdex 200 10/300 gel ﬁltration column
(GE Healthcare) equilibrated in 20 mM Tris pH 7.5, 200 mM NaCl,
1 mM DTT. Samples (100 μL) were injected at a ﬂow rate of 0.5 mL/
min and size exclusion was followed by inline measurement of static
light scattering (DAWN 8+, Wyatt Technology) and differential
refractive index (Optilab T-rEX, Wyatt Technology). The data were
analysed using Astra6 (Wyatt Technology).
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